

## Corporate Profile

<b>Headquarters</b>	Marlborough, Massachusetts <i>Offices also located in Fort Lee, New Jersey; Mississauga, Ontario / Canada</i>
<b>Employees</b>	More than 1,350 employees
<b>Leadership</b>	<p>Hiroshi Nomura, <i>Vice Chair, Executive Vice President and Chief Financial Officer</i></p> <p>Hiroyuki Baba, <i>Executive Vice President, Corporate Strategy</i></p> <p>Robert Gregorio, <i>Executive Vice President and Chief Administrative Officer</i></p> <p>Antony Loebel, <i>MD, Executive Vice President and Chief Medical Officer</i></p> <p>Albert Parker, II, <i>Executive Vice President, General Counsel and Corporate Secretary</i></p> <p>Richard Russell, <i>Executive Vice President and Chief Commercial Officer</i></p> <p>Matt D'Ambrosio, <i>Senior Vice President and Chief Compliance &amp; Ethics Officer</i></p>
<b>Revenues</b>	Approximately \$1.5 Billion in 2012

## Who We Are

Sunovion Pharmaceuticals Inc. (Sunovion) is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the areas of Psychiatry & Neurology and Respiratory disease areas to improve the lives of patients and their families. Sunovion looks at our patients' needs, and the needs of the healthcare professionals who care for them, and finds practical ways of developing better treatments.

## Our History

Sunovion is the offspring of two scientifically advanced, research-based pharmaceutical companies: Sepracor Inc., in the United States, and Dainippon Sumitomo Pharma Co., Ltd., (DSP) in Japan. With a combined company history stretching back more than 100 years, DSP has a strong research and development presence in areas including the central nervous system. In fact, DSP is one of the few companies to develop three atypical antipsychotics in-house – two of which are available in Asia.

- **1897:** Dainippon Pharmaceutical Co., Ltd. founded
- **1984:** Sepracor Inc. was founded
- **2005:** Dainippon Pharmaceuticals and Sumitomo Pharmaceuticals merge to form DSP
- **2009:** Sepracor was acquired by DSP
- **2010:** Sepracor name was changed to Sunovion Pharmaceuticals Inc.

The name Sunovion brings together two timeless forces – the sun's life-sustaining power and the human power of innovation. It is a name and visual brand identity that resonates in both the United States and Japan. Sunovion is a U.S. company with international perspective leveraging global research and drug development. Looking ahead, the company seeks to expand its global footprint as demonstrated by the recent establishment of Sunovion Pharmaceuticals Europe Ltd., formerly Dainippon Sumitomo Pharma Europe Ltd., in the United Kingdom, and Sunovion Pharmaceuticals Asia Pacific Pte Ltd., a wholly-owned subsidiary in Singapore.

## Our Products

The company's development program, together with corporate development and licensing efforts, has yielded a portfolio of pharmaceutical products. These include, Latuda® (lurasidone HCl) tablets, Lunesta® (eszopiclone) tablets, Xopenex® (levalbuterol HCl) inhalation solution, Xopenex HFA® (levalbuterol tartrate) inhalation aerosol, Brovana® (arformoterol tartrate) inhalation solution, Omnaris® (ciclesonide) nasal spray, Zetonna® (ciclesonide) nasal aerosol and Alvesco® (ciclesonide) inhalation aerosol.

## Our Pipeline

Candidate	Indication/Target	Phase I	Phase II	Phase III	NDA Submitted	
<b>Eslicarbazepine acetate</b>	Epilepsy – Adjunct	[Phase I, II, III progress bars]				
<b>Eslicarbazepine acetate</b>	Epilepsy – Adult Monotherapy	[Phase I, II progress bars]				
<b>LATUDA</b>	Major Depressive Disorder (MDD) with Mixed Features	[Phase I, II progress bars]				
<b>SEP-289</b>	Attention-deficit hyperactivity disorder (ADHD)	[Phase I, II progress bars]				
<b>SUN-101</b>	Chronic Obstructive Pulmonary Disease (COPD)	[Phase I, II progress bars]				
<b>DSP-8658</b>	Diabetes and Alzheimer’s Disease	[Phase I progress bar]				
<b>DSP-1053</b>	MDD	[Phase I progress bar]				
<b>DSP-2230</b>	Neuropathic Pain	[Phase I progress bar]				
<b>WT2725</b>	Hematologic and Solid Cancer	[Phase I progress bar]				

*\*Updated as of June 2013*

Additionally, two critical acquisitions in the past two years will help diversify and strengthen the portfolio of the DSP North American business:

- Boston Biomedical, Inc., a biotechnology company dedicated to developing the next generation of targeted cancer therapeutics, allowing DSP to accelerate research and development in oncology
- Elevation Pharmaceuticals, a biotechnology company dedicated to developing novel delivery systems for patients living with COPD, allowing Sunovion to provide another unique option to its existing respiratory portfolio

Sunovion Pharmaceuticals Inc. is an indirect, wholly-owned U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. More information about Sunovion Pharmaceuticals Inc. is available at [www.sunovion.com](http://www.sunovion.com).